Global Avanafil Market by Medication Type (Erectile dysfunction, and Pulmonary hypertension), Product (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, Vitaros and Others), Route of Administration (Oral drugs and Injection), Distribution Channel (Offline & Online) and Dosage (25mg, 50mg, 100mg & 200mg) - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022-2030

Industry Prospective

Avanafil Market size was worth around USD 3.65 billion in 2021 and is predicted to grow around USD 6.12 billion by 2030 with a compound annual growth rate of roughly 6.6% between 2022 and 2030. The report analyzes business drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the market.

Market Overview

Avanafil is used to treat erectile dysfunction in men. Avanafil is a member of the class of medications known as phosphodiesterase 5 (PDE5) inhibitors. These medications slow the activity of an enzyme known as phosphodiesterase type 5.

Erectile dysfunction is the inability to attain or sustain a sufficient penile erection during sexual activity. It is the most prevalent sexual dysfunction in men. Stress has adverse effects on the patient's physical and mental health. There are two primary reasons of erectile dysfunction: physiological causes such as high blood pressure, high cholesterol, obesity, diabetes, and smoking or tobacco usage, and psychological ones such as stress, depression, mental health disorders, etc.

The increase in the number of patients with erectile dysfunction is a primary factor driving the expansion of the erectile dysfunction therapy market. According to a study published in PubMed, which is a database of biomedical and life science topics, the prevalence of erectile dysfunction is high in nations such as the United States, the United Kingdom, Brazil, and China. There are numerous therapies available on the market, including tablets, lotions, injections, and vacuum erection aids.

According to the School of Medicine at the University of Pittsburgh, sales of erectile dysfunction medications increased significantly in 2020 during to the government-mandated lockdown. In the United States, Cialis sales increased the most among all ED medications.

In addition, other factors, such as simple access to ED medications, contributed to the expansion of the erectile dysfunction drug business. Current erectile dysfunction treatments include, among others, vardenafil (Levitra, Staxyn), tadalafil (Adcirca, Cialis), sildenafil (Revatio, Viagra), and avanafil (Stendra).

Key Insights

• As per the analysis shared by our analyst team, the global avanafil market is estimated to grow annually at a CAGR of around 6.6% over the forecast period (2022-2030).
• In terms of revenue, the global avanafil market size was valued at around USD 3.65 Billion in 2021 and is projected to reach USD 6.12 Billion, by 2030. Due to increasing consumption of alcohol and tobacco products, the market is predicted to rise at a significant rate of 6.6%.
• Based on the medication type, the erectile dysfunction was predicted to show maximum market share in the year 2021.
• Based on product, the viagra segment was the leading revenue-generating type in 2021.
• Based on the route of administration, the oral drugs were projected to show largest share in 2021.
• On the basis of distribution channel, the offline segment was dominating the market share in 2021.
• On the basis of dosage, the 50mg segment was projected to show largest share in 2021.
• On the basis of region, North America were the leading revenue generator in 2021.

COVID-19 Impact

Due to increasing product demand, the COVID-19 pandemic had a favorable impact on the sales of erectile dysfunction medications. Nonetheless, the trend in PDE5 sales has accelerated after the pandemic proclamation. Due to this upward tendency, around 24 million units of PDE5 in December 2020 were 67% greater than 14 million units in February 2020. This increase was led by an 85% increase in tadalafil sales. The increase in tadalafil sales was most notable for the 50 mg dosage type, which is authorized for daily consumption.

Increasing Consumption of Alcohol is Expected to Drive the Market

The increasing prevalence of lifestyle diseases such as heart disease, diabetes, stroke, obesity, metabolic syndrome and the increased adoption of a sedentary lifestyle are to blame for the worldwide increase in erectile dysfunction (ED). Moreover, consumption of alcohol and tobacco leads to infertility in semen production significantly enhance the likelihood of erectile dysfunction.
 
Increased acceptability of such detrimental lifestyle choices may fuel market expansion. According to the World Health Organization (WHO), approximately 15% of the male population suffers from erectile dysfunction each year, a number that is expected to increase to 322 million by 2025. Consequently, increasing disease prevalence and increased demand for ED medications are among the primary drivers driving market expansion.

Increasing Awareness Associated with ED Drugs Augmenting the Market Growth

Increasing awareness associated with erectile dysfunction drugs among the population is anticipated to spur market expansion over the forecast period.

• For example, in August 2019, news published by Exchange4media about Pfizer Upjohn, a division of Pfizer Biopharmaceutical Company, launched "#KeepItReal" campaign through online platforms to raise awareness of erectile dysfunction in couples.
• A survey performed in Australia, India, and the United Kingdom resulted in 82% of women believing that their partner should seek therapy for erectile dysfunction.

Concerns Pertaining Side Effects of Avanafil Consumption Sloths Growth

The consumption of avanafil sometimes leads to side effects such as vision changes, dizziness, nausea, pain during erection, numbness or tingling in your chest, arms, neck or jaw, headache, back pain, amongst others. Aforementioned side effects of consuming avanafil are hampering the avanafil market growth.

Segmentation Analysis

Based on medication type, the avanafil market market is segmented into erectile dysfunction and pulmonary hypertension. The erectile dysfunction dominating the market share owing to the geriatric population and growing sedentary lifestyle such as consuming alcohol, smoking, junk foods leading to obesity are contributing the business growth.

Based on product, the global market segments are viagra, cialis, levitra/staxyn, stendra/spedra, zydena, vitaros & others. The viagra segment dominates the market share owing to the huge availability and increased product awareness among erectile dysfunction (ED) in developing countries.

Based on route of administration, the global market segments are oral drugs and injection. The oral drugs segment is dominating the market share owing to the numerous benefits include good patient compliance, safety, intake convenience, pain avoidance, and adaptability to various types of medications.

Based on dosage, the global market segments are 25mg, 50mg, 100mg & 200mg. The 50mg segment is dominating the market share owing to increasing effective rate and usage among millennials.

Based on distribution channel, the global market segments are offline and online. The offline segment is dominating the market share owing to huge availability and easy access contributing the market growth.

Recent Development

June 2022- Adamed has acquired facilities with laboratory infrastructure based in Kajetany near Warsaw to expand laboratory facilities to launch new drug development projects.

November 2019- Mylan and Pfizer announced to form a new company, Viatris to provide the highest-quality medicines to the most patients.

February 2021- Petros Pharmaceuticals has organized a steering committee to pursue enhanced patient access efforts, including non-prescription or Over-the-Counter (OTC) status tactics (ED) for the product, STENDRA® (avanafil) to treat erectile dysfunction.

North America is Dominating the Market Share Owing to Developed Healthcare Infrastructure

North America is dominating the market share of the global avanafil market owing to the presence of major players and increased technological developments. Growing geriatric population, the increase in ED cases, and the improved healthcare infrastructure is favoring the growth in the region.

According to the article released in April 2019 by Rural Health Information Hub, there are more than 46 million older persons aged above 65 in the United States by 2050 and this number is projected to reach about 90 million. As erectile dysfunction is extremely prevalent in men over the age of 40, it is anticipated that the aging of the male population would increase the number of patients in upcoming years. The accessibility of numerous erectile dysfunction medications via over-the-counter (OTC) and online channels is a crucial element in this region's supremacy.

Competitive Landscape

The key players are in avanafil industry includes Viatris Inc., Teva Pharmaceutical Industries Ltd, Century Pharmaceuticals Ltd, SK chemicals, Sun Pharmaceutical Industries Ltd, Bayer AG, Petros Pharmaceuticals, Inc., VIVUS, Inc., Bristol Laboratories Ltd, Adamed, amongst others.

The global Avanafil market is segmented as follows:

By Medication Type

• Erectile dysfunction
• Pulmonary hypertension

By Product

• Viagra
• Cialis
• Levitra/Staxyn
• Stendra/Spedra
• Zydena
• Others

By Route of Administration

• Oral drugs
• Injection

By Distribution Channel

• Offline
• Online

By Dosage

• 25mg
• 50mg
• 100mg
• 200mg

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
• Benelux Reunion
  • • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America